ROYALTY PHARMA APPOINTS VLAD CORIC, M.D. TO BOARD OF DIRECTORS

NEW YORK, NY – Royalty Pharma plc (Nasdaq: RPRX) has announced the appointment of Vlad Coric, M.D., Chairman and CEO of Biohaven, to its Board of Directors, effective immediately.

Dr. Coric brings extensive experience in the biopharmaceutical industry, particularly in neuroscience, immunology and oncology. As the head of Biohaven, he led the company through significant milestones, including the FDA approval and launch of Nurtec ODT for migraine treatment and the submission of a New Drug Application for zavegepant, the first intranasal CGRP antagonist for migraine relief. His leadership was instrumental in Biohaven's growth and its eventual acquisition by Pfizer in 2022 for approximately $13 billion.

“I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric,” said Pablo Legorreta, founder and CEO of Royalty Pharma. “Vlad’s entrepreneurial approach and outstanding leadership skills, honed over a distinguished career in biopharma, will serve as tremendous assets to Royalty Pharma. In addition, Vlad brings notable experience in the royalty funding space, having completed multiple transactions with us during his tenure at Biohaven.”

Before his time at Biohaven, Dr. Coric held research and development roles at Yale School of Medicine and Bristol-Myers Squibb, working across a wide range of therapeutic areas. He is a graduate of Wake Forest University School of Medicine, where he earned his medical degree, and the University of Connecticut, where he studied neurobiology and physiology.